GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taisho Pharmaceutical Holdings Co Ltd (TSE:4581) » Definitions » Shares Outstanding (EOP)

Taisho Pharmaceutical Holdings Co (TSE:4581) Shares Outstanding (EOP) : 82 Mil (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Taisho Pharmaceutical Holdings Co Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Taisho Pharmaceutical Holdings Co's shares outstanding for the quarter that ended in Dec. 2023 was 82 Mil.

Taisho Pharmaceutical Holdings Co's quarterly shares outstanding increased from Sep. 2023 (82 Mil) to Dec. 2023 (82 Mil). It means Taisho Pharmaceutical Holdings Co issued new shares from Sep. 2023 to Dec. 2023 .

Taisho Pharmaceutical Holdings Co's annual shares outstanding increased from Mar. 2022 (82 Mil) to Mar. 2023 (82 Mil). It means Taisho Pharmaceutical Holdings Co issued new shares from Mar. 2022 to Mar. 2023 .


Taisho Pharmaceutical Holdings Co Shares Outstanding (EOP) Historical Data

The historical data trend for Taisho Pharmaceutical Holdings Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taisho Pharmaceutical Holdings Co Shares Outstanding (EOP) Chart

Taisho Pharmaceutical Holdings Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 79.89 79.91 79.91 81.54 82.09

Taisho Pharmaceutical Holdings Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 82.10 82.08 82.09 82.08 82.11

Competitive Comparison of Taisho Pharmaceutical Holdings Co's Shares Outstanding (EOP)

For the Drug Manufacturers - Specialty & Generic subindustry, Taisho Pharmaceutical Holdings Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taisho Pharmaceutical Holdings Co's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taisho Pharmaceutical Holdings Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Taisho Pharmaceutical Holdings Co's Shares Outstanding (EOP) falls into.



Taisho Pharmaceutical Holdings Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Taisho Pharmaceutical Holdings Co  (TSE:4581) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Taisho Pharmaceutical Holdings Co Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Taisho Pharmaceutical Holdings Co's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Taisho Pharmaceutical Holdings Co (TSE:4581) Business Description

Traded in Other Exchanges
Address
3-24-1 Takada, Toshima-ku, Tokyo, JPN, 170-8655
Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan.

Taisho Pharmaceutical Holdings Co (TSE:4581) Headlines

No Headlines